



EXPRESS MAIL NO: EV 000875242 US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN THE APPLICATION OF:

CASE NO.: DM-7029

Brown et al.

SERIAL NO.: 09/454,868

GROUP ART UNIT: 1647

FILED: December 3, 1999

EXAMINER: S. Gucker

FOR: USE OF THE KCNQ2 AND KCNQ3 GENES FOR THE DISCOVERY OF AGENTS USEFUL IN THE TREATMENT OF NEUROLOGICAL DISORDERS

September 27, 2001

Box Sequence
Asst. Commissioner for Patents
Washington, D.C. 20231

**SUBMISSION OF "SEQUENCE LISTING", COMPUTER READABLE COPY,
AND AMENDMENT PERTAINING THERETO**

Sir:

In response to the Office Action dated March 27, 2001, for which a response was due April 27, 2001, please amend the above-identified application as follows. A petition for five (5) months extension of time has been submitted herewith, thus extending the period of time for response to September 27, 2001. Thus, this response is timely. Claims 1-24 are pending.

A copy of the Office Letter is enclosed.

Submitted herewith are:

1. "Sequence Listings", in hard copy, for the nucleotide and/or amino acid sequences in this application.
2. A copy of each "Sequence Listing" submitted for this application in computer readable form.
3. An amendment to the description and claims, wherein reference is made to the sequences by use of the assigned identifiers.
4. A statement that the content of each "Sequence Listing" submitted and each computer readable copy are the same.
5. A statement that the submission includes no new matter.

RECEIVED
OCT 03 2001

TECH CENTER 1600/2900

#8/a
DMT
103-01